Syncona Limited - Issue of Shares Pursuant to Incentive Scheme

Syncona

19/07/2024 10:36

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240719:nRSS0160Xa&default-theme=true

RNS Number : 0160X  Syncona Limited  19 July 2024

Syncona Limited

Issue of shares pursuant to incentive scheme and PDMR dealings

19 July 2024

Syncona Ltd (the "Company"), a leading life science investor focused on
creating, building and scaling global leaders in life science, today announces
that a total of 407,966 new ordinary shares (representing approximately 0.06%
of the Company's existing issued ordinary shares, excluding shares held in
treasury) will be issued in satisfaction of realisations under the Company's
long term incentive scheme.  The new ordinary shares, when issued, will rank
pari passu with the existing issued ordinary shares of the Company. In
accordance with the rules of the incentive scheme, the number of ordinary
shares to be issued has been calculated using the closing mid-market price on
17 July, 2024, £1.25.

In accordance with the rules of the incentive scheme, ordinary shares
delivered on realisation may not be sold or transferred by the recipient for a
period of one year following the realisation date.

The issue of shares includes the following shares to be issued to senior
members of the Syncona Investment Management Limited (SIML) leadership team:

 Name             SIML Title               No. of shares to be issued
 Chris Hollowood  Chief Executive Officer  134,082

Application will be made to the Financial Conduct Authority for the shares to
be admitted to the Official List, and to the London Stock Exchange for the
shares to be admitted to trading and it is expected that dealings will
commence in the new ordinary shares on 24 July 2024.

Notification of transactions by Persons Discharging Managerial
Responsibilities ("PDMRs") are set out below.

 ENDS 

 

Enquiries

 

Syncona Ltd

 

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating, building and scaling companies to deliver transformational
treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading
life science businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on developing
treatments that deliver patient impact by working in close partnership with
world-class academic founders and experienced management teams. Our balance
sheet underpins our strategy, enabling us to take a long-term view as we look
to improve the lives of patients with no or poor treatment options, build
sustainable life science companies and deliver strong risk-adjusted returns to
shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should
seek to ensure they understand the risks and opportunities of an investment
in Syncona Limited, including the information in our published documentation,
before investing.

Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com (http://www.synconaltd.com/)

 

 1.  Details of PDMR / person closely associated with them ("PCA")
 a)  Name                                     Chris Hollowood
 2.  Reason for the notification
 a)  Position / status                        Chair and Chief Executive Officer, SIML
 b)  Initial notification / amendment         Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Syncona Limited
 b)  LEI                                      213800X8MBI5VQITLW60
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary shares

                                              GG00B8P59C08
 b)  Nature of the transaction                Issue of shares pursuant to the Syncona long term incentive scheme
 c)  Price(s) and volume(s)                   Price(s)  Volume(s)

                                              £1.25     134,082
 d)  Aggregated information

     Aggregated volume

     Price                                    N/A
 e)  Date of the transaction                  18 July 2024
 )   Place of the transaction                 Outside a trading venue
 g)  Currency                                 GBP - British Pound

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

18 July 2024

)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAXXPFLLLEFA